Search research articles
Contact Us
Filters
Showing results (161-170 of 212) with videos related to
Page
of 22
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
December 11, 2020
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis
Elizabeth Punnoose, Franklin V Peale, Edith Szafer-Glusman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2016
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Qian Shi, Christopher R Flowers, Wolfgang Hiddemann, et al.
Leukemia & Lymphoma
|
February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia
Alessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.
Hematological Oncology
|
March 20, 2021
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma
Elisa Genuardi, Petra Klous, Barbara Mantoan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2017
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma
Stefano Luminari, Angela Ferrari, Martina Manni, et al.
The Lancet. Oncology
|
May 17, 2014
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial
Umberto Vitolo, Annalisa Chiappella, Silvia Franceschetti, et al.
Haematologica
|
August 21, 2020
A three-gene signature based on <i>MYC</i>, <i>BCL-2</i> and <i>NFKBIA</i> improves risk stratification in diffuse large B-cell lymphoma
Enrico Derenzini, Saveria Mazzara, Federica Melle, et al.
Hematological Oncology
|
June 17, 2020
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity
Luigi Rigacci, Ombretta Annibali, Sofya Kovalchuk, et al.
Leukemia & Lymphoma
|
February 17, 2016
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)
Monica Balzarotti, Ercole Brusamolino, Emanuele Angelucci, et al.
British Journal of Haematology
|
October 13, 2015
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen
Maurizio Musso, Giuseppe Messina, Nicola Di Renzo, et al.
Page
of 22
Search research articles
Search
Showing results (161-170 of 212) with videos related to
Sort By:
Page
of 22
Clinical Lymphoma, Myeloma & Leukemia
|
December 11, 2020
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis
Elizabeth Punnoose, Franklin V Peale, Edith Szafer-Glusman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2016
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Qian Shi, Christopher R Flowers, Wolfgang Hiddemann, et al.
Leukemia & Lymphoma
|
February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia
Alessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.
Hematological Oncology
|
March 20, 2021
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma
Elisa Genuardi, Petra Klous, Barbara Mantoan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2017
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma
Stefano Luminari, Angela Ferrari, Martina Manni, et al.
The Lancet. Oncology
|
May 17, 2014
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial
Umberto Vitolo, Annalisa Chiappella, Silvia Franceschetti, et al.
Haematologica
|
August 21, 2020
A three-gene signature based on <i>MYC</i>, <i>BCL-2</i> and <i>NFKBIA</i> improves risk stratification in diffuse large B-cell lymphoma
Enrico Derenzini, Saveria Mazzara, Federica Melle, et al.
Hematological Oncology
|
June 17, 2020
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity
Luigi Rigacci, Ombretta Annibali, Sofya Kovalchuk, et al.
Leukemia & Lymphoma
|
February 17, 2016
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)
Monica Balzarotti, Ercole Brusamolino, Emanuele Angelucci, et al.
British Journal of Haematology
|
October 13, 2015
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen
Maurizio Musso, Giuseppe Messina, Nicola Di Renzo, et al.
Page
of 22